Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN
Conditions
Interventions
Setanaxib
Pembrolizumab
+1 more
Locations
24
United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Siteman Cancer Center - St. Peters
City of Saint Peters, Missouri, United States
Siteman Cancer Center - West County
Creve Coeur, Missouri, United States
Siteman Cancer Center - North County
Florissant, Missouri, United States
Washington University School of Medicine Center for Advanced Medicine
St Louis, Missouri, United States
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, Grand Est, France
Start Date
April 6, 2022
Primary Completion Date
February 18, 2024
Completion Date
August 21, 2025
Last Updated
September 2, 2025
NCT04895709
NCT05952934
NCT06385080
NCT06487403
NCT06242470
NCT05553782
Lead Sponsor
Calliditas Therapeutics Suisse SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions